Dopamine agonists in Parkinson’s disease

References

• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol.5, 235–245 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain125, 861–870 (2002).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease. Mov. Disord.20, 523–539 (2005).
   PubMed Web of Science ®Google Scholar
• Pahwa R, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia [an evidence-based review]: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66, 983–995 (2006).
   PubMed Web of Science ®Google Scholar
• Olanow CW. Single blind double observer-controlled study of arbidopa/levodopa vs bromocriptine in untreated Parkinson patients. Arch. Neurol.45, 205 (1988).
   Google Scholar
• Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA278, 125–130 (1997).
   PubMed Web of Science ®Google Scholar
• Adler CH, Sethi KD, Hauser RA et al. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology49, 393–399 (1997).
   PubMed Web of Science ®Google Scholar
• Barone P, Bravi D, Bermejo-Pareja F et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology53, 573–579 (1999).
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Elton RL. Low dosages of bromocriptine added to levodopa in Parkinson’s disease. Neurology35, 199–206 (1985).
   PubMed Web of Science ®Google Scholar
• Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. The 053 Study Group. Neurology53, 364–370 (1999).
   PubMed Web of Science ®Google Scholar
• Rinne UK, Bracco F, Chouza C et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology48, 363–368 (1997).
   PubMed Web of Science ®Google Scholar
• Rinne UK, Bracco F, Chouza C et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs55(Suppl. 1), 23–30 (1998).
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology49, 724–728 (1997).
   PubMed Web of Science ®Google Scholar
• Staal-Schreinemachers AL, Wesseling H, Kamphuis DJ, vd Burg W, Lakke JP. Low-dose bromocriptine therapy in Parkinson’s disease: double-blind, placebo-controlled study. Neurology36, 291–293 (1986).
   PubMedGoogle Scholar
• Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson’s disease. Neurology35, 291–295 (1985).
   PubMed Web of Science ®Google Scholar
• Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group. Neurology49, 1060–1065 (1997).
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Nisipeanu P, Rabey JM et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology47, 785–788 (1996).
   PubMed Web of Science ®Google Scholar
• Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology49, 162–168 (1997).
   PubMed Web of Science ®Google Scholar
• Lieberman A, Olanow CW, Sethi K et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology51, 1057–1062 (1998).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Fahn S, Muenter M et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov. Disord.9, 40–47 (1994).
   PubMed Web of Science ®Google Scholar
• Toyokura Y, Mizuno Y, Kase M, Sobue I et al. Effects of bromocriptine on parkinsonism. A nation-wide collaborative double-blind study. Acta Neurol. Scand.72, 157–170 (1985).
   PubMed Web of Science ®Google Scholar
• Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch. Neurol.64(5), 676–682 (2007).
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N et al.; on behalf of the SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol.6(6), 513–520 (2007).
   PubMed Web of Science ®Google Scholar
• Schapira AH. Excessive daytime sleepiness in Parkinson’s disease. Neurology63, S24–S27 (2004).
   PubMed Web of Science ®Google Scholar
• Peralta C, Wolf E, Alber H et al. Valvular heart disease in Parkinson’s disease vs. controls: an echocardiographic study. Mov. Disord.21, 1109–1113 (2006).
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case–control study. Neurology67, 1225–1229 (2006).
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N. Engl. J. Med.356(1), 39–46 (2007).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med.342, 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61, 1044–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Schapira AHV, Olanow CW. The medical management of Parkinson’s disease. In: Principles of Treatment in Parkinson’s Disease. Schapira AH, Olanow CW (Eds). Butterworth Heinemann, PA, USA, 119–143 (2006).
   Google Scholar
• Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson’s disease. Trends Neurosci.23, S2–S7 (2000).
   PubMed Web of Science ®Google Scholar
• Damiano AM, McGrath MM, Willian MK et al. Evaluation of a measurement strategy for Parkinson’s disease: assessing patient health-related quality of life. Qual. Life Res.9, 87–100 (2000).
   PubMed Web of Science ®Google Scholar
• Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology41, 202–205 (1991).
   PubMed Web of Science ®Google Scholar
• Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci.23, S117–S126 (2000).
   PubMed Web of Science ®Google Scholar
• Fahn S, Oakes D, Shoulson I, Kieburtz K et al. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.351, 2498–2508 (2004).
   PubMed Web of Science ®Google Scholar
• Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson’s disease. Neurology58, S1–S8 (2002).
   PubMed Web of Science ®Google Scholar
• Oertel WH, Wolters E, Sampaio C et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov. Disord.21, 343–353 (2006).
   PubMed Web of Science ®Google Scholar
• Schapira AH. Treatment options in the modern management of Parkinson’s disease. Arch. Neurol.64, 1083–1088 (2007).
   PubMed Web of Science ®Google Scholar
• Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety11, 58–65 (2000).
   PubMed Web of Science ®Google Scholar
• Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J. Neurol.253, 601–607 (2006).
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J. Neurol. Sci.248, 266–270 (2006).
   PubMed Web of Science ®Google Scholar
• Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson’s disease. Clin. Neuropharmacol.26, 109–111 (2003).
   PubMed Web of Science ®Google Scholar
• Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther.303, 791–804 (2002).
   PubMed Web of Science ®Google Scholar
• Schapira AH. Science, medicine, and the future: Parkinson’s disease. BMJ318, 311–314 (1999).
   PubMed Web of Science ®Google Scholar
• Schapira AH. Disease modification in Parkinson’s disease. Lancet Neurol.3, 362–368 (2004).
   PubMed Web of Science ®Google Scholar
• Ravina BM, Fagan SC, Hart RG et al. Neuroprotective agents for clinical trials in Parkinson’s disease: a systematic assessment. Neurology60, 1234–1240 (2003).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson’s disease. Ann. Neurol.44, S167–S174 (1998).
   PubMed Web of Science ®Google Scholar
• Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J. Neural. Transm.104, 209–228 (1997).
   PubMed Web of Science ®Google Scholar
• Cassarino DS, Fall CP, Smith TS, Bennett JP Jr. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem.71, 295–301 (1998).
   PubMed Web of Science ®Google Scholar
• Takashima H, Tsujihata M, Kishikawa M, Freed WJ. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D2receptors. Exp. Neurol.159, 98–104 (1999).
   PubMed Web of Science ®Google Scholar
• Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem.91, 1075–1081 (2004).
   PubMed Web of Science ®Google Scholar
• Asanuma M, Ogawa N, Nishibayashi S, Kawai M, Kondo Y, Iwata E. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Arch. Int. Pharmacodyn. Ther.329, 221–230 (1995).
   PubMedGoogle Scholar
• Ferger B, Teismann P, Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res.883, 216–223 (2000).
   PubMed Web of Science ®Google Scholar
• Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res.838, 51–59 (1999).
   PubMed Web of Science ®Google Scholar
• Ogawa N, Tanaka K, Asanuma M et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res.657, 207–213 (1994).
   PubMed Web of Science ®Google Scholar
• Opacka-Juffry J, Wilson AW, Blunt SB. Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res.810, 27–33 (1998).
   PubMed Web of Science ®Google Scholar
• Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem.96, 1315–1321 (2006).
   PubMed Web of Science ®Google Scholar
• Parkinson Disease Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA287, 1653–1661 (2002).
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol.54, 93–101 (2003).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Olanow CW. Neuroprotection in Parkinson disease JAMA291, 358–364 (2004).
   PubMed Web of Science ®Google Scholar
• Marek K, Jennings D, Tabamo R, Seibyl J. InSPECT: an investigation of the effect of short-term treatment with pramipexole or levodopa on [123I] B-CIT and SPECT imaging in early Parkinson disease. Neurology66, A112 (2006).
   PubMed Web of Science ®Google Scholar
• Hilker R, Schweitzer K, Coburger S et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol.62, 378–382 (2005).
   PubMed Web of Science ®Google Scholar
• Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol.59, 1541–1550 (2002).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann. Neurol.59, 559–562 (2006).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Bezard E, Brotchie J et al. Novel pharmacological targets for the treatment of Parkinson’s disease. Nat. Rev. Drug Discov.5, 845–854 (2006).
   PubMed Web of Science ®Google Scholar